NASDAQ:QURE - Uniqure Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$34.41 -0.43 (-1.23 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$34.41
Today's Range$33.98 - $35.3790
52-Week Range$4.90 - $35.75
Volume274,217 shs
Average Volume398,270 shs
Market Capitalization$1.21 billion
P/E Ratio-11.70
Dividend YieldN/A
Beta0.15

About Uniqure (NASDAQ:QURE)

Uniqure logouniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394

Debt

Debt-to-Equity Ratio0.16
Current Ratio5.48
Quick Ratio5.48

Price-To-Earnings

Trailing P/E Ratio-11.70
Forward P/E Ratio-12.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.11 million
Price / Sales96.98
Cash FlowN/A
Price / CashN/A
Book Value$2.71 per share
Price / Book12.70

Profitability

EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-586.38%
Return on Equity-131.55%
Return on Assets-44.52%

Miscellaneous

Employees202
Outstanding Shares36,950,000

Uniqure (NASDAQ:QURE) Frequently Asked Questions

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) issued its quarterly earnings data on Monday, April, 30th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.15. The biotechnology company had revenue of $3.48 million for the quarter, compared to analyst estimates of $3.08 million. Uniqure had a negative net margin of 586.38% and a negative return on equity of 131.55%. View Uniqure's Earnings History.

When is Uniqure's next earnings date?

Uniqure is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Uniqure.

What price target have analysts set for QURE?

8 brokers have issued 12 month target prices for Uniqure's shares. Their forecasts range from $13.00 to $63.00. On average, they anticipate Uniqure's stock price to reach $35.25 in the next twelve months. View Analyst Ratings for Uniqure.

Are investors shorting Uniqure?

Uniqure saw a decrease in short interest in April. As of April 13th, there was short interest totalling 751,751 shares, a decrease of 29.8% from the March 30th total of 1,070,529 shares. Based on an average daily trading volume, of 322,800 shares, the days-to-cover ratio is presently 2.3 days. Approximately 3.9% of the shares of the stock are sold short.

Who are some of Uniqure's key competitors?

Who are Uniqure's key executives?

Uniqure's management team includes the folowing people:
  • Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 46)
  • Dr. Sander Van Deventer, Co-Founder, Chief Scientific Officer, Director, Advisor & GM of Amsterdam (Age 64)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan Ph.D., Chief Operating Officer (Age 59)
  • Mr. Christian Klemt, Chief Accounting Officer (Age 45)

Has Uniqure been receiving favorable news coverage?

Media coverage about QURE stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Uniqure earned a media sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Uniqure's major shareholders?

Uniqure's stock is owned by many different of retail and institutional investors. Top institutional investors include FORUNIQURE B.V. (13.81%), COLLER INTERNATIONAL PARTNERS V A LP (5.73%), Federated Investors Inc. PA (2.89%), Millennium Management LLC (2.06%), Foresite Capital Management IV LLC (1.52%) and BlackRock Inc. (1.37%). Company insiders that own Uniqure stock include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor and Matthew C Kapusta. View Institutional Ownership Trends for Uniqure.

Which major investors are selling Uniqure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Foresite Capital Management IV LLC, BlackRock Inc. and Barclays PLC. Company insiders that have sold Uniqure company stock in the last year include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor and Matthew C Kapusta. View Insider Buying and Selling for Uniqure.

Which major investors are buying Uniqure stock?

QURE stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Millennium Management LLC, Eventide Asset Management LLC, Sphera Funds Management LTD., venBio Select Advisor LLC, Spark Investment Management LLC, California Public Employees Retirement System and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Uniqure.

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $34.41.

How big of a company is Uniqure?

Uniqure has a market capitalization of $1.21 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]


MarketBeat Community Rating for Uniqure (QURE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  604
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Uniqure (NASDAQ:QURE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Uniqure in the last 12 months. Their average twelve-month price target is $35.25, suggesting that the stock has a possible upside of 2.44%. The high price target for QURE is $63.00 and the low price target for QURE is $13.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.862.752.71
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.25$23.8333$20.8571$16.8333
Price Target Upside: 2.44% upside26.01% downside15.73% downside6.47% upside

Uniqure (NASDAQ:QURE) Consensus Price Target History

Price Target History for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018SunTrust BanksInitiated CoverageBuy$48.00HighView Rating Details
5/22/2018HC WainwrightReiterated RatingBuy$42.00HighView Rating Details
5/16/2018Wells Fargo & CoInitiated CoverageOutperform$47.00MediumView Rating Details
5/7/2018Leerink SwannReiterated RatingOutperform ➝ Outperform$26.00 ➝ $63.00LowView Rating Details
4/30/2018Chardan CapitalReiterated RatingBuyHighView Rating Details
3/20/2018Janney Montgomery ScottReiterated RatingBuy$30.00HighView Rating Details
11/24/2017OppenheimerReiterated RatingHoldLowView Rating Details
11/7/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$22.00N/AView Rating Details
5/24/2017CowenReiterated RatingBuyMediumView Rating Details
4/12/2017Jefferies GroupReiterated RatingHold$8.00LowView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 ➝ $15.00N/AView Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Uniqure (NASDAQ:QURE) Earnings History and Estimates Chart

Earnings by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ:QURE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.81)($0.81)($0.81)
Q2 20182($0.80)($0.67)($0.74)
Q3 20182($0.81)($0.71)($0.76)
Q4 20182($0.48)($0.16)($0.32)

Uniqure (NASDAQ QURE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
4/30/20183/31/2018($0.74)($0.59)$3.08 million$3.48 millionViewN/AView Earnings Details
3/14/2018Q4 2017($0.68)($0.91)$2.83 million$2.58 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.65)($0.40)$7.60 million$2.26 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.78)($0.83)$2.92 million$4.94 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.52)($0.58)$6.60 million$9.13 millionViewN/AView Earnings Details
11/22/2016Q3 2016($0.86)($0.60)$4.10 million$7.21 millionViewN/AView Earnings Details
8/25/2016Q2 2016($0.87)($0.98)$4.08 million$1.82 millionViewN/AView Earnings Details
5/31/2016Q1($0.8220)($0.9250)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.1410)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.9820)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.8160)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Uniqure (NASDAQ:QURE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Uniqure (NASDAQ QURE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 43.83%
Insider Trading History for Uniqure (NASDAQ:QURE)
Institutional Ownership by Quarter for Uniqure (NASDAQ:QURE)

Uniqure (NASDAQ QURE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Matthew C KapustaCEOSell39,169$21.72$850,750.68439,764View SEC Filing  
1/29/2018David SchafferDirectorSell2,878$18.53$53,329.3415,314View SEC Filing  
1/29/2018Deventer Sander VanInsiderSell5,985$18.53$110,902.05View SEC Filing  
1/4/2018Matthew C. KapustaCEOSell21,690$19.87$430,980.30View SEC Filing  
1/3/2018Christian KlemtInsiderSell5,093$20.13$102,522.09View SEC Filing  
1/3/2018Maria E. CantorSVPSell5,864$20.13$118,042.32View SEC Filing  
6/29/2017Harald PetryInsiderSell49,300$6.02$296,786.0027,753View SEC Filing  
6/27/2017Harald PetryInsiderSell65,930$6.01$396,239.30155View SEC Filing  
6/26/2017Harald PetryInsiderSell58,075$6.01$349,030.75155View SEC Filing  
6/22/2017Harald PetryInsiderSell155$6.00$930.00155View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Uniqure (NASDAQ QURE) News Headlines

Source:
DateHeadline
SunTrust Banks Initiates Coverage on Uniqure (QURE)SunTrust Banks Initiates Coverage on Uniqure (QURE)
www.americanbankingnews.com - May 24 at 1:14 PM
UPDATE: SunTrust Robinson Humphrey Starts uniQure BV (QURE) at BuyUPDATE: SunTrust Robinson Humphrey Starts uniQure BV (QURE) at Buy
www.streetinsider.com - May 24 at 8:45 AM
Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene TherapyChardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy
www.streetinsider.com - May 23 at 5:11 PM
Uniqure (QURE) Stock Rating Reaffirmed by HC WainwrightUniqure (QURE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - May 22 at 12:54 PM
Traders Purchase High Volume of Call Options on Uniqure (QURE)Traders Purchase High Volume of Call Options on Uniqure (QURE)
www.americanbankingnews.com - May 22 at 6:59 AM
UniQures AMT-060 shows treatment benefit in hemophilia B patients with pre-existing neutralizing antibodies; shares ...UniQure's AMT-060 shows treatment benefit in hemophilia B patients with pre-existing neutralizing antibodies; shares ...
seekingalpha.com - May 21 at 4:53 PM
Uniqure NV (QURE) Receives Consensus Rating of "Buy" from BrokeragesUniqure NV (QURE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 3:34 PM
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 ...uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 ...
globenewswire.com - May 21 at 8:42 AM
uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction ...uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction ...
www.streetinsider.com - May 21 at 8:42 AM
BRIEF-Uniqure Presents New Data In Hemophilia B PatientsBRIEF-Uniqure Presents New Data In Hemophilia B Patients
www.reuters.com - May 21 at 8:42 AM
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing AntibodiesuniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
finance.yahoo.com - May 21 at 8:42 AM
Uniqure Notches Bullish Initiation On Gene Therapy ProspectsUniqure Notches Bullish Initiation On Gene Therapy Prospects
www.benzinga.com - May 20 at 5:28 PM
uniQure Presents Preclinical Data Demonstrating Advances inuniQure Presents Preclinical Data Demonstrating Advances in
www.lse.co.uk - May 18 at 9:23 AM
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene TherapyuniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
finance.yahoo.com - May 18 at 9:23 AM
Uniqure NV (QURE) Expected to Announce Quarterly Sales of $3.55 MillionUniqure NV (QURE) Expected to Announce Quarterly Sales of $3.55 Million
www.americanbankingnews.com - May 18 at 5:00 AM
BRIEF-ForUniQure Reports 13.81 Percent Passive Stake In UniQureBRIEF-ForUniQure Reports 13.81 Percent Passive Stake In UniQure
www.reuters.com - May 17 at 8:58 AM
Uniqure (QURE) Earns Outperform Rating from Analysts at Wells FargoUniqure (QURE) Earns Outperform Rating from Analysts at Wells Fargo
www.americanbankingnews.com - May 16 at 1:49 PM
Wells Fargo Starts uniQure BV (QURE) at OutperformWells Fargo Starts uniQure BV (QURE) at Outperform
www.streetinsider.com - May 16 at 8:58 AM
Zacks: Analysts Expect Uniqure NV (QURE) Will Post Earnings of -$0.68 Per ShareZacks: Analysts Expect Uniqure NV (QURE) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - May 16 at 3:12 AM
BidaskClub Upgrades Uniqure (QURE) to Strong-BuyBidaskClub Upgrades Uniqure (QURE) to Strong-Buy
www.americanbankingnews.com - May 15 at 12:36 AM
3 Cutting-Edge Biotech Stocks That Can Double in Value3 Cutting-Edge Biotech Stocks That Can Double in Value
finance.yahoo.com - May 13 at 9:04 AM
Uniqure NV (QURE) to Post FY2018 Earnings of ($2.11) Per Share, Leerink Swann ForecastsUniqure NV (QURE) to Post FY2018 Earnings of ($2.11) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 9 at 8:32 AM
Equities Analysts Offer Predictions for Uniqure NVs Q2 2018 Earnings (QURE)Equities Analysts Offer Predictions for Uniqure NV's Q2 2018 Earnings (QURE)
www.americanbankingnews.com - May 8 at 5:52 AM
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters Option To Purchase Additional ...uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional ...
globenewswire.com - May 7 at 5:12 PM
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters Option To Purchase Additional SharesuniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - May 7 at 5:12 PM
Uniqure (QURE) Given Outperform Rating at Leerink SwannUniqure (QURE) Given Outperform Rating at Leerink Swann
www.americanbankingnews.com - May 7 at 2:58 PM
uniQure (QURE) Prices 4.5M Share Offering at $28.50/ShuniQure (QURE) Prices 4.5M Share Offering at $28.50/Sh
www.streetinsider.com - May 3 at 4:58 PM
BRIEF-Uniqure NV Says On May 2, Co & Leerink Mutually Terminated Sales Agreement Related To At-The-Market ...BRIEF-Uniqure NV Says On May 2, Co & Leerink Mutually Terminated Sales Agreement Related To At-The-Market ...
www.reuters.com - May 3 at 8:44 AM
Uniqure (QURE) Upgraded to Strong-Buy by ValuEngineUniqure (QURE) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
Chardan Capital Reiterates Buy Rating for Uniqure (QURE)Chardan Capital Reiterates Buy Rating for Uniqure (QURE)
www.americanbankingnews.com - May 2 at 11:45 AM
uniQure (QURE) Commences 4M Public Offering of Ordinary SharesuniQure (QURE) Commences 4M Public Offering of Ordinary Shares
www.streetinsider.com - May 2 at 8:49 AM
Uniqure (QURE) Issues Quarterly  Earnings Results, Beats Expectations By $0.15 EPSUniqure (QURE) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - May 1 at 10:11 AM
Uniqure (QURE) PT Set at $35.00 by HC WainwrightUniqure (QURE) PT Set at $35.00 by HC Wainwright
www.americanbankingnews.com - May 1 at 10:01 AM
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell ...uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell ...
globenewswire.com - April 30 at 4:54 PM
uniQure Announces First Quarter 2018 Financial Results and Highlights Company ProgressuniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
globenewswire.com - April 30 at 8:53 AM
UniQure: 1Q Earnings SnapshotUniQure: 1Q Earnings Snapshot
finance.yahoo.com - April 30 at 8:53 AM
 Brokerages Anticipate Uniqure NV (QURE) Will Announce Quarterly Sales of $3.08 Million Brokerages Anticipate Uniqure NV (QURE) Will Announce Quarterly Sales of $3.08 Million
www.americanbankingnews.com - April 30 at 2:58 AM
Uniqure NV (QURE) Sees Significant Drop in Short InterestUniqure NV (QURE) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 29 at 3:12 AM
-$0.74 Earnings Per Share Expected for Uniqure NV (QURE) This Quarter-$0.74 Earnings Per Share Expected for Uniqure NV (QURE) This Quarter
www.americanbankingnews.com - April 28 at 3:14 PM
uniQure Announces to Present at Multiple Conferences in MayuniQure Announces to Present at Multiple Conferences in May
finance.yahoo.com - April 27 at 9:08 AM
Uniqure NV (QURE) Given Average Rating of "Buy" by AnalystsUniqure NV (QURE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 26 at 3:30 PM
uniQure Delivers Oral Presentation on Broad Set of PreclinicuniQure Delivers Oral Presentation on Broad Set of Preclinic
www.lse.co.uk - April 25 at 5:09 PM
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntingtons Disease at the 2018 ...uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington's Disease at the 2018 ...
globenewswire.com - April 25 at 5:09 PM
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual MeetinguniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 25 at 5:09 PM
Uniqure (QURE) Given a $35.00 Price Target at HC WainwrightUniqure (QURE) Given a $35.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 23 at 9:48 AM
Opinion: Harry Boxers biotech-stock breakouts to watchOpinion: Harry Boxer's biotech-stock breakouts to watch
www.marketwatch.com - April 20 at 8:55 AM
Uniqure (QURE) Rating Increased to Hold at ValuEngineUniqure (QURE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Analyst Ratings for UniQure and Its Peers in April 2018Analyst Ratings for UniQure and Its Peers in April 2018
finance.yahoo.com - April 13 at 5:06 PM
An In-Depth Look at UniQure’s Cash Flows and ValuationAn In-Depth Look at UniQure’s Cash Flows and Valuation
finance.yahoo.com - April 13 at 5:06 PM
Insights into UniQure’s Financial PerformanceInsights into UniQure’s Financial Performance
finance.yahoo.com - April 13 at 5:06 PM

SEC Filings

Uniqure (NASDAQ:QURE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Uniqure (NASDAQ:QURE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Uniqure (NASDAQ QURE) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.